← Back to Search
Evidence Of RNAi In Humans From Systemically Administered SiRNA Via Targeted Nanoparticles
M. Davis, Jonathan E Zuckerman, C. Choi, D. Seligson, A. Tolcher, C. Alabi, Y. Yen, J. Heidel, A. Ribas
Published 2010 · Medicine, Biology
Download PDFAnalyze on Scholarcy
Therapeutics that are designed to engage RNA interference (RNAi) pathways have the potential to provide new, major ways of imparting therapy to patients. Long, double-stranded RNAs were first shown to mediate RNAi in Caenorhabditis elegans, and the potential use of RNAi for human therapy has been demonstrated by the finding that small interfering RNAs (siRNAs; approximately 21-base-pair double-stranded RNA) can elicit RNAi in mammalian cells without producing an interferon response. We are at present conducting the first in-human phase I clinical trial involving the systemic administration of siRNA to patients with solid cancers using a targeted, nanoparticle delivery system. Here we provide evidence of inducing an RNAi mechanism of action in a human from the delivered siRNA. Tumour biopsies from melanoma patients obtained after treatment show the presence of intracellularly localized nanoparticles in amounts that correlate with dose levels of the nanoparticles administered (this is, to our knowledge, a first for systemically delivered nanoparticles of any kind). Furthermore, a reduction was found in both the specific messenger RNA (M2 subunit of ribonucleotide reductase (RRM2)) and the protein (RRM2) levels when compared to pre-dosing tissue. Most notably, we detect the presence of an mRNA fragment that demonstrates that siRNA-mediated mRNA cleavage occurs specifically at the site predicted for an RNAi mechanism from a patient who received the highest dose of the nanoparticles. Together, these data demonstrate that siRNA administered systemically to a human can produce a specific gene inhibition (reduction in mRNA and protein) by an RNAi mechanism of action.
This paper references
RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent anti-viral strategy
R Alvarez (2009)
RNAi therapeutics: a potential new class of pharmaceutical drugs
D. Bumcrot (2006)
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Sayda M. Elbashir (2001)
RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy
R. Alvarez (2009)
First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.
S. Leachman (2010)
The promises and pitfalls of RNA-interference-based therapeutics
D. Castanotto (2009)
Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia
M. Koldehoff (2007)
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
A. Fire (1998)
Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging
D. Bartlett (2006)
Impact of tumor‐specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA‐containing nanoparticles
D. Bartlett (2008)
an appealing target in anti-tumor therapy
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
M. Kleinman (2008)
The measured resolution at which images were acquired is 512 3 512 pixels, and the image bit-depth is 8-bit. The Zeiss LSM Image Browser Software allows the extraction of images
Efficient delivery of siRNA for inhibition of gene expression in postnatal mice
D. L. Lewis (2002)
Patient RNA samples were reversed-transcribed using SuperScriptIII reverse transcriptase. White blood cell (WBC) cDNA (0.4–200 ng) was used as a
The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.
M. Davis (2009)
Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements
Thomas Schluep (2009)
Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy.
N. A. Cerqueira (2005)
from concept to clinic
Au-PEG-AD staining of CALAA-01 nanoparticles in tumor biopsy samples using Au-PEG-AD and DAPI nuclear counter-stain. All pre-treatment samples
-Peg-Ad Dapi Au
Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In vitro and In vivo
J. Heidel (2007)
Supplementary Information is linked to the online version of the paper at www.nature.com/nature
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA
J. Heidel (2007)
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
J. Soutschek (2004)
California 91010, USA. 7 Calando Pharmaceuticals, 201 South Lake Avenue, Suite 703
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging
D. Bartlett (2007)
RNA interference targeting Fas protects mice from fulminant hepatitis
E. Song (2003)
Transferrin receptors in human tissues: their distribution and possible clinical relevance.
K. Gatter (1983)
Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV).
J. Devincenzo (2008)
RNA interference in adult mice
A P Mccaffrey (2002)
Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment.
A. Juhász (2006)
Comparative studies on the ultrastructure of malignant melanoma in fish and human by freeze-etching and transmission electron microscopy
R. Riehl (2004)
Elevated expression of M1 and M2 components and drug-induced posttranscriptional modulation of ribonucleotide reductase in a hydroxyurea-resistant mouse cell line.
G. McClarty (1987)
This paper is referenced by
PSMA-targeted theranostic nanoplex for prostate cancer therapy.
Z. Chen (2012)
Metal use in ribonucleotide reductase R2, di-iron, di-manganese and heterodinuclear--an intricate bioinorganic workaround to use different metals for the same reaction.
M. Högbom (2011)
Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspective.
J. Zhang (2013)
Folate-decorated PEGylated triblock copolymer as a pH/reduction dual-responsive nanovehicle for targeted intracellular co-delivery of doxorubicin and Bcl-2 siRNA.
A. Suo (2017)
Multicolor Upconversion Nanoparticles for Protein Conjugation
S. Wilhelm (2013)
microRNAs as Therapeutic Targets to Combat Diverse Human Diseases
Elizabeth Hong-Geller (2011)
Intracellular drug delivery using laser activated carbon nanoparticles
Aritra Sengupta (2014)
Office of Cancer Nanotechnology Research Center for Strategic Scientific Initiatives (CSSI)
Ultrasound-responsive microbubbles for sonography-guided siRNA delivery.
P. Wang (2016)
NANOPARTICLES: STATE-OF-THE- ART AND REMAINING CHALLENGES
Gaurav Bajaj (2013)
Nano-encapsulation of Oligonucleotides for Therapeutic Use
Eveline E. Salcher (2014)
Design of multifunctional gold nanoparticles for in vitro and in vivo gene silencing.
João Conde (2012)
A Portrait of Nanomedicine and its Bioethical Implications
Rebecca M. Hall (2012)
Personalized Medicine: Where Do We Go from Here?
Dipanjan Pan (2015)
A biodegradable adamantane polymer with ketal linkages in its backbone for gene therapy.
Santanu Maity (2015)
RGDS covalently surfaced nanodiamond as a tumor targeting carrier of VEGF-siRNA: synthesis, characterization and bioassay.
Chunying Cui (2015)
EFFECTS OF CORE AND SHELL MODIFICATION TO TETHERED NANOASSEMBLIES ON SIRNA THERAPY
Steven Rheiner (2017)
Src Family Kinases in Intracerebral Hemorrhage
Dazhi Liu (2014)
Gene Inactivation Strategies: An Update
Chang-an Guo (2014)
Molecular Biology of Kidney Cancer
William G. KaelinJr. (2012)
Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells.
J. H. Trembley (2012)
Development of controlled drug delivery systems for bone fracture‐targeted therapeutic delivery: A review
Yuchen Wang (2018)
Peptide Spiders: Peptide-Polymer Conjugates to Traffic Nucleic Acids.
E. Kwon (2020)
Supramolecular Linear-g-Hyperbranched Graft Polymers: Topology and Binding Strength of Hyperbranched Side Chains
Christian M. Moers (2013)
Recycling Gene Carrier with High Efficiency and Low Toxicity Mediated by L-Cystine-Bridged Bis(β-cyclodextrin)s
Yu-hui Zhang (2014)
DsRNA degradation in the pea aphid (Acyrthosiphon pisum) associated with lack of response in RNAi feeding and injection assay
O. Christiaens (2014)
Challenges and opportunities for siRNA-based cancer treatment.
Tao Wang (2017)
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Edgar Pérez-Herrero (2015)
Enhanced silencing and stabilization of siRNA polyplexes by histidine-mediated hydrogen bonds.
Szu-Ting Chou (2014)
Targeting ribonucleotide reductase for cancer therapy
J. Shao (2013)
ADVANCES IN TRANSLATIONAL SCIENCE
J. Sellin (2012)
Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexes.
X. Ming (2011)See more